Johnson & Johnson's Profit, Sales Rise
January 22 2020 - 7:29AM
Dow Jones News
By Dave Sebastian
Johnson & Johnson said its profit and sales rose for the
fourth quarter, roughly in line with Wall Street estimates.
The New Jersey-based health-products company reported net income
of $4.01 billion, or $1.50 a share, compared with $3.04 billion, or
$1.12 a share, in the year-ago period. Excluding special items,
Johnson & Johnson earned $1.88 a share.
Analysts polled by FactSet were expecting adjusted earnings of
$1.87 a share.
World-wide sales rose to $20.75 billion from $20.39 billion for
the same period in the prior year. Analysts were looking for $20.8
billion.
U.S. sales rose 1.4% to $10.77 billion from the comparable
quarter a year earlier, and international sales rose 2.1% to $9.97
billion.
Sales in the company's pharmaceuticals division rose 3.5% to
$10.55 billion. Sales in its medical-devices business fell 0.5% to
$6.63 billion. Sales of consumer products, which include Neutrogena
beauty products and Tylenol medicine, rose 0.9% to $3.57
billion.
For 2020, the company said it sees operational sales of $85.8
billion to $86.6 billion. The company expects adjusted operational
sales to grow 5% to 6% from a year earlier.
Johnson & Johnson guided adjusted per-share earnings of
$8.95 to $9.10.
J&J has had a series of costly legal setbacks. In August, an
Oklahoma judge ordered the company to pay $572 million for
contributing to the state's opioid-addiction crisis. Overall,
J&J is facing lawsuits from about 100,000 plaintiffs over the
safety and marketing of products including Johnson's Baby Powder,
opioids and medical devices.
(END) Dow Jones Newswires
January 22, 2020 07:14 ET (12:14 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024